Cetuximab in Treating Patients With Advanced Solid Tumors

Inclusion Criteria:

* Signed written informed consent
* Histologically or cytologically proven advanced solid tumors not curable by surgery, radiation therapy or standard chemo-, immuno-, or hormonal therapy. A specific primary cancer need not have been identified (i.e., unknown primary is eligible).
* Patients must have received at least one prior regimen (chemotherapy and/or radiation) for metastatic disease. There is no limit to the number of prior therapies.
* Any prior chemotherapy must have been completed at least 4 weeks prior to start of study therapy. Previous radiation therapy must have been completed at least 2 weeks prior to start of study therapy. All side effects of prior therapy must be resolved prior to the start of study therapy.
* Patients with ZUBROD performance status 0-2 (see Appendix 1).
* Patients must have measurable disease or evaluable disease.
* Patients must have an estimated survival of at least 3 months.
* Patients with asymptomatic treated brain metastasis (surgical resection or radiotherapy) may be included if they are neurologically stable and have been off steroids for at least 4 weeks.
* Patients \>/= 18 years of age.
* Patients of reproductive potential must agree to use an effective contraceptive method while on treatment and for 3 months afterward as the effects of cetuximab on the unborn fetus are unknown.
* Patients must have adequate hematologic function defined as: ANC \>/= 1,500/mm3, platelets \>/= 100,000/mm3.
* Patients must have adequate hepatic function defined as SGOT \</= 3 x institutional UNL and serum bilirubin \</= 2.0 mg/dL.
* Patients must have adequate renal function defined as a serum creatinine level \</= 1.6 mg/dL or a calculated creatinine clearance of \>/= 40 ml/min.

Exclusion Criteria:

* Female patients cannot be pregnant or breastfeeding as the effects of cetuximab on the unborn fetus are unknown. Documentation of a negative pregnancy test prior to treatment is required for all women of reproductive potential.
* Uncontrolled intercurrent illness including but not limited to ongoing infection or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
* Patients with symptomatic brain metastasis or still requiring steroids.
* Patients who have received prior cetuximab therapy, prior therapy with any other drug that targets the EGF receptor (including, but not limited to, Iressa, Tarceva, Herceptin, CI1033, etc.), or prior therapy with a monoclonal antibody.
* Patients who have received prior chemotherapy within 4 weeks or radiation therapy within 2 weeks prior to the start of study therapy.
* Prior hypersensitivity reaction to chimerized or murine monoclonal antibody therapy.
* Patients may not receive any other chemotherapy, radiation therapy, or biologic therapy while on study.